Processa Pharmaceuticals Files Prospectus For Offering 306.574M Common Shares On Behalf Of Selling Shareholders
https://www.sec.gov/ix?doc=/Archives/edgar/data/1533743/000114036126039267/ny20083166x1_pre14a.htm
Stocks · News reference
Processa Pharmaceuticals shares are trading lower after the company announced a $200 million private placement and acquisition of Vidya Therapeutics BTK Inhibitor VT-7208.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K/A filing — Processa Pharmaceuticals, Inc. (PCSA)
Filed: 2026-10-05 AccNo: 0001140361-26-038535 Size: 3 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
8-K filing — Processa Pharmaceuticals, Inc. (PCSA)
Filed: 2026-08-04 AccNo: 0001493152-26-036032 Size: 226 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits
Crude Oil Surges 7%; General Dynamics Posts Upbeat Earnings
Dow Jones falls 800+ pts; energy shares up 2.6%; General Dynamics beats earnings estimates; Verra Mobility reaches agreement with Avis.